HighField Biopharmaceuticals
  • Home
  • Platforms
    • ADCplex Platform
    • TCEplex Platform
    • TCTplex Platform
  • Pipeline
    • K16: Immune Modulator
    • K1: Lipid-based Antibody Drug Complex
    • HF50: T cell Engager
    • HFG!: GLP-1R Agonist
  • Facilities
  • About
  • News & Publications
  • Contact
  • zh_CN简体中文
HighField Biopharmaceuticals
  • Home
  • Platforms
    • ADCplex Platform
    • TCEplex Platform
    • TCTplex Platform
  • Pipeline
    • K16: Immune Modulator
    • K1: Lipid-based Antibody Drug Complex
    • HF50: T cell Engager
    • HFG!: GLP-1R Agonist
  • Facilities
  • About
  • News & Publications
  • Contact
  • zh_CN简体中文

Search Posts

About Us

Lorem ipsum dolor sit amet, consectetur adipisc
glelit, sed do eiusmod tempor incididunt .ut labo
et dolore magna aliqua.

Blog Categories

  • HighField in the News (4)
  • Press Release (19)
  • Publications (16)
  • References (21)
  • Uncategorized (6)
  • Video (1)

Recent Posts

June 16, 2026

HighField Biopharmaceuticals Launches Phase 2 Trial of K16, a First-in-Class Lipid-Based Drug for Recurrent and Progressive Brain Cancer

by PJWCreative
December 4, 2025

HighField Biopharmaceuticals Presents Clinical Trial Sample Analysis of 2 Novel Lipid-Based Immuno-Oncology Therapeutics at the Society for Immunotherapy of Cancer (SITC) 2025 Meeting

by PJWCreative
Post placeholder image
November 9, 2025

SITC 2025 Poster: Targeting MDSCs with HF1K16 Unlocks Long-Term Survival in Refractory Recurrent Glioma: an update of NCT05388487

by HighField Bio
Post placeholder image
November 9, 2025

SITC 2025 Poster: First-in-Human Evaluation of HF50, a Novel Liposomal HER2xCD3 T Cell Engager with TLR Agonist Payload, Demontrates Tolerability and Early Clinical Response

by HighField Bio
October 31, 2025

Clinical Data of Two HighField Biopharmaceuticals Immuno-Oncology Lipid-Based Therapeutics Accepted for Late-Breaking Abstract Presentations at the 40th Anniversary Meeting of the Society for Immunotherapy of Cancer (SITC) Nov. 5 – 9, 2025.

by HighField Bio
Post placeholder image
July 31, 2025

Video 1 Test

by PJWCreative

Recent Comments

No comments to show.

Tags

General HF50 HFG1 K1 K16

Post placeholder image
November 9, 2025 in Publications

SITC 2025 Poster: Targeting MDSCs with HF1K16 Unlocks Long-Term Survival in Refractory Recurrent Glioma: an update of NCT05388487

HighField Bio 0 Like Post Comments Off on SITC 2025 Poster: Targeting MDSCs with HF1K16 Unlocks Long-Term Survival in Refractory Recurrent Glioma: an update of NCT05388487

Click here  

Read More
Post placeholder image
November 9, 2025 in Publications

SITC 2025 Poster: First-in-Human Evaluation of HF50, a Novel Liposomal HER2xCD3 T Cell Engager with TLR Agonist Payload, Demontrates Tolerability and Early Clinical Response

HighField Bio 0 Like Post Comments Off on SITC 2025 Poster: First-in-Human Evaluation of HF50, a Novel Liposomal HER2xCD3 T Cell Engager with TLR Agonist Payload, Demontrates Tolerability and Early Clinical Response

Click here  

Read More
Post placeholder image
August 8, 2024 in Publications

ASCO Breakthrough 2024 Poster: Exploratory phase I study of HF1K16 for the treatment of patients with refractory/recurrent advanced glioma

PJWCreative 0 Like Post Comments Off on ASCO Breakthrough 2024 Poster: Exploratory phase I study of HF1K16 for the treatment of patients with refractory/recurrent advanced glioma

Click here

Read More
Post placeholder image
June 21, 2024 in Publications

American Diabetes Association 2024 Poster: Preliminary study of efficacy and duration of an mRNA based GLP-1R agonist in diabetic monkeys

HighField Bio 0 Like Post Comments Off on American Diabetes Association 2024 Poster: Preliminary study of efficacy and duration of an mRNA based GLP-1R agonist in diabetic monkeys

Click here

Read More
Post placeholder image
February 12, 2023 in Publications

Liposomes : Methods and Protocols: Preparation and Characterization of Trastuzumab Fab-Conjugated Liposomes (Immunoliposomes)

PJWCreative 0 Like Post Comments Off on Liposomes : Methods and Protocols: Preparation and Characterization of Trastuzumab Fab-Conjugated Liposomes (Immunoliposomes)

Click here

Read More
Post placeholder image
August 30, 2022 in Publications

mAbs : Liposomal T cell Engager and Re-director for Tumor Cell Eradication in Cancer Immunotherapy

PJWCreative 0 Like Post Comments Off on mAbs : Liposomal T cell Engager and Re-director for Tumor Cell Eradication in Cancer Immunotherapy

Click here

Read More
Post placeholder image
April 12, 2022 in Publications

Frontiers in Immunology : Sustained Drug Release from Liposomes for the Remodeling of Systemic Immune Homeostatis and the Tumor Microenvironment

PJWCreative 0 Like Post Comments Off on Frontiers in Immunology : Sustained Drug Release from Liposomes for the Remodeling of Systemic Immune Homeostatis and the Tumor Microenvironment

Click here

Read More
Post placeholder image
January 10, 2022 in Publications

Pharmaceutical Research: Biodistribution and Non-linear Gene Expression of MRNA LNPs Affected by Delivery Route and Particle Size

PJWCreative 0 Like Post Comments Off on Pharmaceutical Research: Biodistribution and Non-linear Gene Expression of MRNA LNPs Affected by Delivery Route and Particle Size

Click here

Read More
Post placeholder image
August 31, 2021 in Publications

Pharmaceutical Research: Surface Ligand Valency and Immunoliposome Binding: When More is Not Always Better

PJWCreative 0 Like Post Comments Off on Pharmaceutical Research: Surface Ligand Valency and Immunoliposome Binding: When More is Not Always Better

Click here

Read More
Post placeholder image
September 9, 2020 in Publications

Advanced Drug Delivery Reviews: When Liposomes Met Antibodies: Drug Delivery and Beyond

PJWCreative 0 Like Post Comments Off on Advanced Drug Delivery Reviews: When Liposomes Met Antibodies: Drug Delivery and Beyond
Read More
Prev12Next

Download Company Profile

Home
Platforms
Pipeline
Facilities
About
News & Publications

Contact Us

Follow Us

Linkedin Weixin

© 2023-26 HighField Biopharmaceuticals, Inc.   Terms of Use.       
LipoADCplex™ and TRAFsome™ are trademarks of HighField Biopharmaceuticals, Inc

en_US English
en_US English
zh_CN 简体中文